Sunmax Biotechnology Co Ltd Cash Flow-to-Debt Ratio
Sunmax Biotechnology Co Ltd cash flow-to-debt ratio. Sunmax Biotechnology Co Ltd (4728) has a Cash Flow-to-Debt Ratio of 0.35x as of September 2025, meaning its operating cash flow of NT$160.84 Million could theoretically repay 0% of its total liabilities (NT$454.35 Million) in one year. Check how high is Sunmax Biotechnology Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sunmax Biotechnology Co Ltd (2015–2024)
Cash flow-to-debt ratio of Sunmax Biotechnology Co Ltd from 2015 to 2024. Historical debt coverage capacity for Sunmax Biotechnology Co Ltd across 10 annual periods. Check Sunmax Biotechnology Co Ltd (4728) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sunmax Biotechnology Co Ltd Cash Flow-to-Debt Ratio by Year (2015–2024)
Sunmax Biotechnology Co Ltd cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Sunmax Biotechnology Co Ltd. For the full cash flow conversion analysis, see Sunmax Biotechnology Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.18x | NT$397.37 Million | NT$337.82 Million | ▲ +1.6% |
| 2023 | 1.16x | NT$848.56 Million | NT$732.99 Million | ▲ +58.0% |
| 2022 | 0.73x | NT$342.97 Million | NT$468.00 Million | ▲ +38.7% |
| 2021 | 0.53x | NT$243.28 Million | NT$460.44 Million | ▼ -35.1% |
| 2020 | 0.81x | NT$386.97 Million | NT$475.27 Million | ▲ +22.6% |
| 2019 | 0.66x | NT$289.51 Million | NT$435.82 Million | ▼ -27.6% |
| 2018 | 0.92x | NT$100.83 Million | NT$109.88 Million | ▲ +118.2% |
| 2017 | 0.42x | NT$37.09 Million | NT$88.22 Million | ▲ +7.0% |
| 2016 | 0.39x | NT$16.58 Million | NT$42.20 Million | ▲ +176.3% |
| 2015 | -0.52x | NT$-22.84 Million | NT$44.33 Million | — |